Biogen BIIB Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 75.5%-0.2pp | 75.7%+0.5pp | 75.2%-0.2pp | 75.4%-0.1pp | 75.6%-0.5pp | |
| Net margin | 14.3%+0.7pp | 13.6%-2.4pp | 16%+0.7pp | 15.3%+0.2pp | 15.1%-1.8pp | |
| EBITDA margin | 27%+0.8pp | 26.2%-2.3pp | 28.5%+1.1pp | 27.4%+0.4pp | 26.9%-1.7pp | |
| Free cash flow margin | 24.4%+3.6pp | 20.7%-2.2pp | 22.9%+3.1pp | 19.8%-5.0pp | 24.8%-3.3pp | |
| Returns | ||||||
| Return on equity | 8%+0.3pp | 7.7%-1.6pp | 9.3%+0.2pp | 9.1%-0.1pp | 9.2%-1.2pp | |
| Return on assets | 4.9%+0.3pp | 4.7%-0.9pp | 5.6%0.0pp | 5.6%+0.1pp | 5.4%-0.5pp | |
| Return on invested capital | 7.8%+0.8pp | 7%-1.8pp | 8.8%+0.7pp | 8%-0.1pp | 8.1%-0.4pp | |
| Efficiency | ||||||
| Asset turnover | 0.3×0.0× | 0.3×0.0× | 0.4×0.0× | 0.4×0.0× | 0.4×0.0× | |
| Inventory turnover | 19×-1.1× | 20.1×+0.7× | 19.4×+0.7× | 18.8×-3.8× | 22.6×-3.7× | |
| Liquidity | ||||||
| Current ratio | 3.1×+0.4× | 2.7×0.0× | 2.7×+0.2× | 2.5×+1.1× | 1.4×+0.1× | |
| Quick ratio | 3×+0.4× | 2.6×0.0× | 2.7×+0.2× | 2.5×+1.0× | 1.4×+0.1× | |
| Cash ratio | 1.1×+0.2× | 0.9×-0.3× | 1.2×+0.3× | 0.9×+0.4× | 0.5×+0.1× | |
| Leverage | ||||||
| Debt-to-equity | 0.4×0.0× | 0.4×0.0× | 0.4×0.0× | 0.4×+0.1× | 0.3×-0.1× | |
| Debt-to-assets | 0.2×0.0× | 0.2×0.0× | 0.2×0.0× | 0.2×+0.1× | 0.2×-0.1× | |
| Net debt / EBITDA | 1.2×-0.2× | 1.4×+0.5× | 1×-0.5× | 1.4×+0.5× | 0.9×-0.7× | |
| Per Share | ||||||
| Book value per share | $125.69+1.3% | $124.11+0.3% | $123.78+3.0% | $120.20+3.8% | $115.82+1.1% | |
| Valuation | ||||||
| Market capitalization | $26.91B+4.2% | $25.82B+25.7% | $20.54B+11.0% | $18.51B-7.6% | $20.03B-10.1% | |
| Enterprise value | $30.08B+2.1% | $29.47B+26.7% | $23.27B+4.1% | $22.34B+0.2% | $22.3B-16.2% | |
| Price / earnings | 18.9×-0.3× | 19.2×+6.5× | 12.8×+0.7× | 12.1×-1.4× | 13.5×-0.1× | |
| Price / sales | 2.7×+0.1× | 2.6×+0.6× | 2×+0.2× | 1.9×-0.2× | 2×-0.3× | |
| Price / book | 1.4×0.0× | 1.4×+0.3× | 1.1×+0.1× | 1×-0.1× | 1.2×-0.2× | |
| EV / EBITDA | 11.2×-0.2× | 11.4×+3.3× | 8.1×-0.1× | 8.2×-0.3× | 8.4×-1.2× | |
| EV / sales | 3×0.0× | 3×+0.7× | 2.3×+0.1× | 2.2×0.0× | 2.3×-0.5× | |
| Free cash flow yield | 9%+1.1pp | 7.9%-3.3pp | 11.2%+0.5pp | 10.7%-1.5pp | 12.2%0.0pp | |
| Earnings yield | 5.3%+0.1pp | 5.2%-2.6pp | 7.8%-0.4pp | 8.3%+0.9pp | 7.4%+0.1pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Biogen's profit margins?
- Biogen (BIIB) runs a 75.5% gross margin and a 22.9% operating margin, with a 14.3% net margin.
- Where do Biogen's ratios come from?
- Every ratio is computed from Biogen's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
